Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

117.04
+4.544.04%
Post-market: 119.382.34+2.00%17:09 EDT
Volume:249.20K
Turnover:28.79M
Market Cap:1.57B
PE:-33.16
High:118.88
Open:114.32
Low:109.97
Close:112.50
52wk High:151.18
52wk Low:18.23
Shares:13.44M
Float Shares:8.40M
Volume Ratio:0.84
T/O Rate:2.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5291
EPS(LYR):-7.8322
ROE:-301.19%
ROA:-47.54%
PB:40.65
PE(LYR):-14.94

Loading ...

Palvella - Achieved Statistical Significance on Pre-Specified Key Secondary Endpoint (P<0.001) & All 4 Secondary Efficacy Endpoints (All P<0.001)

THOMSON REUTERS
·
Feb 24

Palvella Therapeutics to Host Call on Phase 3 SELVA Topline Results for QTORIN Rapamycin Gel in Microcystic Lymphatic Malformations

Reuters
·
Feb 24

Palvella Therapeutics COO Kathleen Goin Disposes of Common Shares

Reuters
·
Feb 21

Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum

TIPRANKS
·
Feb 18

Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA)

TIPRANKS
·
Feb 16

Analysts’ Top Healthcare Picks: Cogstate Ltd (COGZF), Palvella Therapeutics (PVLA)

TIPRANKS
·
Feb 13

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Feb 10

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Progyny (PGNY)

TIPRANKS
·
Feb 09

Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Feb 03

Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating

TIPRANKS
·
Feb 03

Palvella Therapeutics management to meet virtually with Craig-Hallum

TIPRANKS
·
Feb 02

Palvella Therapeutics to Advance QTORIN Pitavastatin into Phase 2 Trials for Porokeratosis

Reuters
·
Feb 02

Palvella Therapeutics Inc : TD Cowen Raises Target Price to $190 From $133

THOMSON REUTERS
·
Feb 02

Analysts’ Top Healthcare Picks: Danaher (DHR), Palvella Therapeutics (PVLA)

TIPRANKS
·
Jan 31

Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG

Dow Jones
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Jan 29

Palvella Therapeutics (PVLA) Receives a Buy from BTIG

TIPRANKS
·
Jan 21

Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG

Dow Jones
·
Jan 17

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)

TIPRANKS
·
Jan 16

Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics

TIPRANKS
·
Jan 14